MedTrace Logo

Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM

NCT05395689 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2024-07-18

No results posted yet for this study

Summary

The trial is performed to assess efficacy and safety of Beltavac with polymerized extract of house dust mites in allergic Rhinoconjunctivitis associated or not with asthma

Conditions

  • House Dust Mite Allergy

Interventions

BIOLOGICAL

House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae

The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year

BIOLOGICAL

Placebo

The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year

Sponsors & Collaborators

  • Probelte Pharma S.L.U.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-17
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05395689 on ClinicalTrials.gov